Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

Fig. 1

PBSC mobilization metrics. a Proportions of patients with delayed mobilization are shown. b Peripheral blood CD34+ cell counts at the first LP are depicted. c CD34 + cell collection results after the first LP session are shown. d Percentages of patients with distinct numbers of LP sessions are displayed. Abbreviations: bw, body weight; d, days; Elo, elotuzumab; Isa, isatuximab; LP, leukapheresis; PB, peripheral blood; PBSC, peripheral blood stem cells, RVd, lenalidomide, bortezomib, dexamethasone

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us